TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 135 filers reported holding TG THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $17,120,623 | +7851.8% | 689,236 | +3687.0% | 0.05% | +5200.0% |
| Q4 2022 | $215,306 | +11.6% | 18,200 | -44.1% | 0.00% | 0.0% |
| Q3 2022 | $193,000 | -61.4% | 32,547 | -72.3% | 0.00% | -50.0% |
| Q2 2022 | $500,000 | -77.6% | 117,698 | +75.2% | 0.00% | -75.0% |
| Q3 2021 | $2,236,000 | -35.3% | 67,196 | -24.6% | 0.01% | -33.3% |
| Q2 2021 | $3,457,000 | -30.0% | 89,123 | -13.0% | 0.01% | -45.5% |
| Q1 2021 | $4,938,000 | -53.8% | 102,455 | -50.1% | 0.02% | -53.2% |
| Q4 2020 | $10,687,000 | +90.1% | 205,448 | -2.2% | 0.05% | +113.6% |
| Q3 2020 | $5,622,000 | -38.7% | 210,084 | -55.4% | 0.02% | -52.2% |
| Q2 2020 | $9,177,000 | +2470.6% | 471,089 | +641.5% | 0.05% | +4500.0% |
| Q3 2019 | $357,000 | -72.3% | 63,533 | -57.4% | 0.00% | -80.0% |
| Q2 2019 | $1,290,000 | -15.4% | 149,236 | -21.3% | 0.01% | -16.7% |
| Q1 2019 | $1,525,000 | +44.5% | 189,736 | +136.4% | 0.01% | +50.0% |
| Q2 2018 | $1,055,000 | – | 80,250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 6,880,323 | $38,633,000 | 2.30% |
| Eversept Partners, LP | 773,501 | $4,343,208 | 1.35% |
| Opaleye Management Inc. | 612,500 | $3,439,000 | 1.24% |
| BRIDGER MANAGEMENT, LLC | 2,334,196 | $13,107,000 | 1.08% |
| Sofinnova Investments, Inc. | 1,733,628 | $9,734,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 354,719 | $1,992,000 | 0.34% |
| 683 Capital Management, LLC | 400,000 | $2,246,000 | 0.25% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 649,460 | $3,646,000 | 0.23% |
| Artal Group S.A. | 900,000 | $5,054,000 | 0.20% |
| Frontier Wealth Management LLC | 226,750 | $1,273,000 | 0.19% |